CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Cue Biopharma, Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today that it will participate in this year's BIO CEO & Investor Conference in New York, NY. This event takes place February 13-14, 2017 at the Waldorf Astoria Hotel.
Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma is scheduled to present an overview of the company’s approach to modulating the human immune system and its lead programs on Monday, February 13, 2017 at 9:15 a.m. ET in the Park North room. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
About Cue Biopharma
Immune Responses, On Cue. Cue Biopharma™ (Cue) is an immunotherapy company developing biologics engineered to selectively communicate with disease-relevant T cell subsets to treat cancer and autoimmune disease. Cue biologics have the potential to be highly effective as monotherapies as well as synergistic with existing checkpoint inhibitors, while reducing collateral toxicities often seen with less selective immunotherapies. Through this platform approach, Cue has developed a promising pipeline with its lead candidate currently approaching the clinic. Headquartered in Kendall Square, Cambridge, MA, Cue is led by a strong, experienced management team and scientific advisory board (SAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
For more information, visit www.cuebio.com.